Clinical Trials Logo

Clinical Trial Summary

More people worldwide use amphetamine-type stimulants than any illicit drug besides cannabis, and methamphetamine (MA) abuse and dependence is the fastest growing drug problem in the United States. Much work remains in identifying an effective pharmacotherapy for MA dependence. The neurobiological actions produced by MA involve dopamine (DA), serotonin, and norepinephrine, but also include alterations to cholinergic neurotransmitter systems. Candidate compounds that target acetylcholine (ACh) are attractive options for development that have not received adequate attention. Varenicline is a drug that increases the release of DA in the brain and it is logical to assume that it would to some extent compensate for the reduction in these neurotransmitters that occurs in MA withdrawal.

Current research has linked certain genes that are related to neurotransmitters with drug abuse and memory impairment (e.g., A1 allele for the D2 dopamine receptor and catechol-O-methyltransferase). We will take blood samples and test for these genes in order to relate the findings to brain function.

This is a double-blind, placebo-controlled, within-subjects study to determine the safety and tolerability of MA in MA-dependent volunteers treated with varenicline and placebo.


Clinical Trial Description

Study Procedures:

Study participants are those who meet criteria for MA dependence, who are not seeking treatment, and who also meet criteria for nicotine dependence. Participants will be asked to wear a telemetry device during screening and throughout the study that records heart rate and body temperature. Participants will be required to refrain from smoking at certain times, illicit and prescription drug use for the duration of the study and this will be confirmed with daily urine testing.

The study consists of 30 days or less of outpatient screening. The 2-component inpatient portion of the study lasts a total of 18 days. Participants will be admitted to the GCRC at UCLA for Days 1-10. After the first study day, participants will be randomized to varenicline or matched placebo for 9-days and then discharged from the GCRC. Then, after 2-4 weeks, the same subjects return to the GCRC to be switched to the alternate condition (placebo or varenicline) for the second component of the study, which lasts another 8-days. Each subject is randomized to both varenicline and placebo, so total time commitment is 18 inpatient study days. One follow-up visit is scheduled 2 weeks after completion of both study phases for assessment of delayed adverse events and for final payment.

On the first day of the inpatient procedure, subjects received 10 3mg infusions of methamphetamine over 2.5 hours for assessment of drug tolerability. On day 9 of the first component and day 7 of the second component, subjects received either 10 3mg infusions of saline OR methamphetamine over 2.5 hours. In the afternoon, the infusion was the opposite of the morning condition. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00713479
Study type Interventional
Source University of California, Los Angeles
Contact
Status Completed
Phase Phase 1
Start date July 2008
Completion date September 2009

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05535101 - Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder N/A
Not yet recruiting NCT02836756 - Cannabidiol as a New Intervention for Amphetamine Dependence Phase 2
Completed NCT03318081 - The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction N/A
Completed NCT03221283 - The Application of Music Therapy in Female Amphetamine Use Disorder N/A
Withdrawn NCT02952196 - Cannabioids as a New Intervention for Amphetamine Dependence Phase 2
Completed NCT02285556 - The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus N/A
Completed NCT02713815 - Novel Intervention for Amphetamine-type Stimulants Addiction N/A
Completed NCT04993300 - Repetitive Transcranial Magnetic Stimulation in Amphetamine Addiction N/A
Completed NCT02950376 - The Novel Addiction Assessment Study in Synthetic Drugs Addiction
Recruiting NCT04531384 - Robot-Assisted Intelligent Rehabilitation Treatment for Methamphetamine Use Disorders. N/A
Recruiting NCT04687566 - Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction Phase 2/Phase 3